NasdaqGM:SUPNPharmaceuticals
Supernus Pharmaceuticals (SUPN): Assessing Valuation After Recent CNS Portfolio Progress and ONAPGO Approval
Supernus Pharmaceuticals (SUPN) has quietly rewarded patient investors, with the stock up around 30% this year and roughly 31% over the past year, outpacing many mid cap biotech peers.
See our latest analysis for Supernus Pharmaceuticals.
That climb has come as management pushed its central nervous system portfolio forward, with FDA approval for ONAPGO adding to optimism. The steady year to date share price return suggests momentum is still building from a longer track record of strong total...